Business Description
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 502.55 | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -3.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 62.1 | |||||
| 3-Year EPS without NRI Growth Rate | 61.9 | |||||
| 3-Year FCF Growth Rate | 64.3 | |||||
| 3-Year Book Growth Rate | -38.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.58 | |||||
| 9-Day RSI | 37.75 | |||||
| 14-Day RSI | 35.42 | |||||
| 6-1 Month Momentum % | -12.41 | |||||
| 12-1 Month Momentum % | -71.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.78 | |||||
| Quick Ratio | 10.78 | |||||
| Cash Ratio | 10.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -143.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -44.78 | |||||
| ROA % | -41.92 | |||||
| ROIC % | -1452.94 | |||||
| ROC (Joel Greenblatt) % | -36235.29 | |||||
| ROCE % | -44.87 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 0.61 | |||||
| EV-to-EBIT | 0.82 | |||||
| EV-to-EBITDA | 0.82 | |||||
| EV-to-FCF | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 0.62 | |||||
| Price-to-Net-Cash | 0.63 | |||||
| Earnings Yield (Greenblatt) % | 121.76 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONCT
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -0.78 | ||
| Beta | 1.44 | ||
| Volatility % | 98.54 | ||
| 14-Day RSI | 35.42 | ||
| 14-Day ATR ($) | 0.073048 | ||
| 20-Day SMA ($) | 0.96544 | ||
| 12-1 Month Momentum % | -71.56 | ||
| 52-Week Range ($) | 0.6902 - 4.49 | ||
| Shares Outstanding (Mil) | 53.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncternal Therapeutics Inc Analysis
Share your researchHeadlines
See More
No news.